retatrutide pharmacokinetics Intranasal retatrutide: nasal spray delivery, bioavailability, all you need to know Retatrutide Significantly Reduces Visceral Fat

Appetite changes often begin within the first 12 weeks

Key Takeaways Retatrutide is being studied as a triple agonist that targets GIP, GLP-1, and glucagon receptors

For example, stimulants like Vyvanse could interact with certain antidepressants or heart medications

There have been post-marketing reports of diabetic retinopathy complications , particularly in patients with pre-existing retinopathy who experience rapid glycaemic improvement

Recent studies showed that patients taking the drug lost 15% to 20% of their body weight over 68 weeks, Insider's Gabby Landsverk previously reported

Every time I went up a little bit I would feel nauseous for like a week and then it would settle down. (P9, female, diabetes)